Financials in USD. Standardized financial statements.
A compact view of how Soleno Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $190.41M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$1.55B | $1.45M |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +100.0% | -107145.4% | 0.0% |
| Cost of Revenue? | $2.70M | $0 | $0 | $0 | $0 | $2.19M | $2.30M | $1.92M | $1.61M | $1.51M |
| Gross Profit? | $187.71M | $0 | $0 | $0 | $0 | -$2.19M | -$2.30M | -$1.92M | -$1.55B | -$58,518 |
| Gross Margin? | +98.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +100.1% | -4.0% |
| Operating Expenses? | $172.75M | $187.67M | $41.38M | $24.40M | $31.53M | $29.75M | $20.90M | $13.73M | $9.68M | $13.55M |
| Operating Income? | $14.95M | -$187.67M | -$41.38M | -$24.40M | -$31.53M | -$31.95M | -$23.20M | -$14.30M | -$12.17M | -$13.61M |
| EBITDA? | $28.38M | -$173.63M | -$37.03M | -$22.10M | -$30.30M | -$22.45M | -$28.48M | -$9.92M | -$8.07M | -$6.72M |
| Income Before Tax | $20.89M | -$175.85M | -$38.99M | -$24.07M | -$30.91M | -$24.64M | -$30.77M | -$11.84M | -$13.72M | -$12.04M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$1.65M | $21,700 |
| Net Income? | $20.89M | -$175.85M | -$38.99M | -$24.07M | -$30.91M | -$24.64M | -$30.77M | -$13.34M | -$15.67M | -$12.07M |
| EPS? | $0.41 | $-4.38 | $-2.36 | $-2.87 | $-5.81 | $-3.68 | $-15.78 | $-9.54 | $-26.18 | $-58.35 |
| Diluted EPS? | $0.39 | $-4.38 | $-2.36 | $-2.87 | $-5.81 | $-3.68 | $-15.78 | $-9.54 | $-26.18 | $-58.35 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality